A framework for understanding and targeting residual disease in oncogene-driven solid cancers.

ABSTRACT: Molecular targeted therapy has the potential to dramatically improve survival in patients with cancer. However, complete and durable responses to targeted therapy are rare in individuals with advanced-stage solid cancers. Even the most effective targeted therapies generally do not induce a complete tumor response, resulting in residual disease and tumor progression that limits patient survival. We discuss the emerging need to more fully understand the molecular basis of residual disease as a prelude to designing therapeutic strategies to minimize or eliminate residual disease so that we can move from temporary to chronic control of disease, or a cure, for patients with advanced-stage solid cancers. Ultimately, we propose a shift from the current reactive paradigm of analyzing and treating

SUBMITTER: Bivona TG 

PROVIDER: S-EPMC5384713 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature